The global peptide therapeutics market is valued at US$ 38.0 billion in 2023 and is expected to reach US$ 106.0 billion by 2033, expanding at a CAGR of 10.8% from 20233 to 2033.
Peptide therapeutics now account for 53.7% of the global drug discovery market, with the Asia Pacific region leading the way in peptide-based drugs. Peptide medicines have been used to treat metabolic illnesses for over a century. Peptide drugs have numerous advantages over tiny chemical compounds, resulting in high demand across geographies.
Request a Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1038
Owing to the benefits related to the consumption of peptide therapeutics as well as the product’s wide range of applications in pharmaceuticals and the biotechnology sector, the market outlook for peptide therapeutics is highly positive in the upcoming years. Manufacturers of peptide therapeutics have realized the vital role that the product can play in meeting unfulfilled medical needs. Further, peptide therapeutics can be a preferred alternative to small molecule and biological therapeutics. All of these factors have led to an upsurge in research and investments in peptide drug recovery over the last ten years and is expected to bode well for the future prospects of the market.
Again, surging incidences of metabolic disorders and high prevalence of cancer propel the demand for investments in research and development activities in the field of peptide therapies. These illnesses are the prime cause of death and disability all over the world. As a result, there a greater demand for the development of peptide therapeutics. Peptide-based drug delivery for cancer cells coupled with enhancements in the next generation therapeutics will presumably supplement the market expansion of peptide therapeutics. In addition to this, there’s a rise in the interest in therapeutic peptide research due to commercial reasons. Thus, it is presumed that peptide drug recovery will play a crucial role in the healthcare industry.
“Heightened application of peptides in the treatment of diabetes and cancer will likely augment the sales of peptide therapeutics in the global market over the forecast period,” says an FMI analyst.
Key Takeaways:
- Popularity of oral peptide-based drugs to generate attractive market opportunities.
- Peptide-based therapeutics will continue to gain momentum in Cosmeceuticals.
- Government support to aid market growth in North America.
- India will offer various lucrative opportunities to the peptide therapeutics industry.
- Based on route of administration, parenteral route segment will continue to gain preference during the assessment period.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-1038
Competitive Landscape
Eli Lilly and Company, AstraZeneca plc, Merck & Co., Inc., Ipsen S.A, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd., among others are some of the major players in the peptide therapeutics market that are profiled in the full version of the report.
In a moderately competitive market, major players are concentrating on market expansion activities. These organizations are engaging in distribution agreements, white space exploration, and collaborative ventures. The more established businesses are focusing on working with local players in order to expand their production capacities and improve their regional presence.
More Insights into the Peptide Therapeutics Market Report
In its latest report, FMI offers an unbiased analysis of the global peptide therapeutics market, providing historical data from 2014 to 2021 and forecast statistics for 2022 to 2025. To understand the global market potential, growth, and range, the market is segmented based on application (cancer, cardiovascular diseases, central nervous systems, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, acromegaly, other applications), route of administration (parenteral route of administration, mucosal route of administration, oral route of administration, transdermal route of administration), drug type (branded drugs, generic/ biosimilar drugs), and region.
Request Report Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-1038
According to the latest FMI reports, based on region, the peptide therapeutics market in North America is expected to dominate the market over the forecast period. A surge in government investments as well as an increase in industry spending on research and development activities in peptide therapeutics is driving the regional market growth. This market is further supported by the target market expansion in the United States. Owing to the high prevalence of cancer along with increasing research and development activities, the U.S. peptide therapeutics market is expected to witness impressive growth over the forecast period.
In India, the peptide therapeutics market is anticipated to gain many profitable future prospects. The rising adoption of synthetic peptide drugs in India is likely to propel the market growth in this region. Rising incidences of chronic illnesses and an ageing population also contribute to the market growth.
Based on segmentation, on the basis of route of administration, the parenteral route will continue to gain momentum over the forecast period.
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
